Tyra Bioscience Initiates Phase 2 Study for Achondroplasia Treatment

Tyra Bioscience has dosed the first child in its BEACH301 Phase 2 clinical study for achondroplasia, with initial safety results expected in H2 2026. Analysts rate the stock a Buy with a $33 price target. Spark's AI Analyst rates TYRA a Neutral due to its high-risk profile, strong liquidity, and negative earnings. Investors should be cautious, considering both growth potential and inherent risks.

Tyra Biosciences, Inc. (Nasdaq: TYRA) has taken a significant step forward in its mission to develop precision medicines for rare genetic disorders. On July 21, 2025, the company announced that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism [1].

Dabogratinib is an oral, FGFR3-selective inhibitor that was discovered using Tyra's proprietary SNÅP platform. This study marks a pivotal moment for Tyra, as it seeks to transform the care of children with achondroplasia by targeting the root cause of the condition. The initial results from the safety sentinel cohort are expected in the second half of 2026.

The BEACH301 study is a multicenter, open-label, dose-escalation/dose-expansion trial enrolling children aged 3 to 10 with achondroplasia. The study will evaluate the drug's safety and tolerability, as well as its impact on growth velocity and other metrics. The trial is enrolling children who are treatment-naïve and those who have received prior growth-accelerating therapy.

Analysts have provided mixed views on Tyra Biosciences' stock. While some analysts rate it a Buy with a $33 price target, others, such as Spark's AI Analyst, have a Neutral rating due to its high-risk profile, strong liquidity, and negative earnings. Investors are advised to consider both the growth potential and the inherent risks associated with the company's high-risk, early-stage development efforts.

Tyra Biosciences is committed to bringing forward innovative and accessible therapies for children and their families. The company's approach with dabogratinib is designed to specifically target FGFR3, generating excitement among families and advocates in the achondroplasia community. The study represents important progress in advancing care for children with achondroplasia and holds the potential to reshape the future for these children and their families.

References:

[1] https://www.marketscreener.com/news/tyra-biosciences-announces-first-child-dosed-in-beach301-its-phase-2-study-for-dabogratinib-tyra-3-ce7c51d3de88f72c